SP1 and inflammatory bowel disease: Indeed, CD IgA bound significantly less Neu5Ac‐2,3‐Gal‐1,4‐Glc‐Sp1 relative to non‐IBD IgA, while two others, SGP and Neu5Ac‐2,3‐Gal‐1,4‐(Fuc‐1,3)‐Glc‐[3‐Sialyl‐3‐fucosyllactose/F‐SL], were significantly more targeted (Appendix Fig S3D and Table S8).